Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

BACKGROUND: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess the efficacy and tolerability of olaparib, a PARP inhibitor, in patients with a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Cancer
Hlavní autoři: Choy, Edwin, Butrynski, James E, Harmon, David C, Morgan, Jeffrey A, George, Suzanne, Wagner, Andrew J, D’Adamo, David, Cote, Gregory M, Flamand, Yael, Benes, Cyril H, Haber, Daniel A, Baselga, Jose M, Demetri, George D
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4230717/
https://ncbi.nlm.nih.gov/pubmed/25374341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-813
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky